ClinicalTrials.gg
CompletedNCT02407990Updated Nov 17, 2021Results posted

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

A Phase 1 interventional study of BGB-A317 and BGB-A317 in Advanced Cancer, sponsored by BeiGene. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
451
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must have had a or cytologically confirmed advanced or tumor for which no effective standard therapy was available.

    1. For Phase 1A: no specific restriction
    2. For Phase 1B: histology specified below:

    i. non-small cell lung cancer (participants with documented epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement should have been excluded) ii. ovarian cancer iii. gastric cancer iv. hepatocellular carcinoma (HCC, Barcelona-Clinic Liver Cancer stage C, stage B not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach, and A) v. head and neck squamous cell carcinoma vi. esophageal carcinoma vii. triple negative breast cancer viii. cholangiocarcinoma ix. renal cell cancer, bladder cancer, melanoma, Merkel-cell carcinoma, sarcoma, gastrointestinal stromal tumor, or cutaneous squamous cell carcinoma. Or any other solid tumors with known microsatellite instability-high or mismatch repair deficient status, such as colorectal cancer or pancreatic cancer

  2. Participants with previously treated (es) that were asymptomatic or radiographically/clinically stable and not requiring medications for 4 weeks prior to enrollment were permitted.
  3. Participants must have had archival tumor tissues or agreed to a tumor for analysis of predictive biomarkers such as programmed death-ligand 1 (). (Fresh tumor biopsies were strongly recommended at baseline for biomarker analysis in participants with readily accessible tumor lesions and who consented to the biopsies).
  4. Participants must have had as defined per Response Evaluation Criteria in Solid Tumor Version 1.1.
  5. performance status of ≤ 1.
  6. Participants must have had adequate organ function as indicated by the following laboratory values:

    • ≥ 1,500 /microliter
    • ≥ 100,000 / milliliter (mL)
    • ≥ 9 grams/deciliter or ≥ 5.6 millimoles/liter
    • Serum creatinine ≤ 1.5 X (ULN)
    • Serum total ≤ 1.5 X ULN
    • (serum glutamic oxaloacetic transaminase) and alanine aminotransferase (serum glutamic pyruvic transaminase) ≤ 2.5 X ULN or ≤ 5 X ULN for participants with liver metastases
    • or prothrombin time ≤ 1.5 X ULN
    • Activated partial thromboplastin time ≤ 1.5 X ULN

Key Exclusion Criteria:

  1. History of severe reactions to other Monoclonal antibodies.
  2. Prior active within the previous 2 years except for tumor for which a participant was enrolled in the study, and locally curable cancers that had been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
  3. Prior therapies targeting PD-1 or PD-L1.
  4. Participants who failed to meet enrollment criteria for other PD-1 or PD-L1 trials solely due to low or negative predictive biomarkers.
  5. Participants with active diseases or history of autoimmune diseases should have been excluded.
  6. Participants should have been excluded if they had a condition requiring systemic treatment with either corticosteroids (> 10 milligrams daily prednisone equivalents) or other medications within 14 days of study drug administration.
  7. Had history of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
  8. Known history of .
  9. Active infection requiring therapy, positive tests for surface antigen or ribonucleic acid except in participant with HCC, who met the following criteria:

    • Hepatitis B virus (HBV) viral load \< 200 international units/mL (approximately 1000 combined positive score/mL)
    • Participants with active HBV infection needed to be on anti-HBV suppression ≥ 3 months, throughout treatment and for 6 months after
    • Participants hepatitis C virus (HCV)-positive after successful treatment (defined as sustained virologic response [SVR] 12 or SVR 24) were allowed as long as 4 weeks had passed between completion of HCV therapy and start of study drug
  10. Use of any vaccines against infectious diseases (for example, influenza, varicella) within 4 weeks (28 days) of initiation of study therapy and 60 days after the last administration of the study medication.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    BGB-A317 Phase 1A

    Biological: BGB-A317

  • Experimental
    BGB-A317 Phase 1B

    Biological: BGB-A317

Interventions

  • BiologicalBGB-A317

    In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.

  • BiologicalBGB-A317

    Participants were assigned to different groups based on their tumor types

06

What researchers measure

Primary outcomes

  1. Phase 1A: Number of Participants Experiencing Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010).

    Time frame: Day -28 through 5 years and 2 months

  2. Phase 1A: Number Of Participants With Abnormal Physical Examination Values

    A complete physical examination, vital signs (systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1A. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.

    Time frame: Day 1 and Day 15 of each cycle through 30 (+/- 7) days after last dose (up to 5 years and 2 months)

  3. Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings

    Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1A. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.

    Time frame: Day 15 of cycle 1, Day 1 of Cycle 2 and all additional cycles, and 30 (+/- 7) days after last dose (up to 5 years and 2 months)

  4. Phase 1A: Number Of Participants With Abnormal Electrocardiograms

    Electrocardiograms were obtained at pre-specified time points. Significant QT interval corrected for heart rate (QTc) prolongation was defined as an interval ≥ 500 milliseconds (msec) or an interval which increases by ≥ 60 msec over baseline.

    Time frame: Days 1 and 15 of cycle 1; Day 1 of cycle 2 and all additional cycles; Day 1 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)

  5. Phase 1A: Number Of Participants With Abnormal Laboratory Values

    Clinical chemistry, hematology, coagulation, and urinalysis were performed at pre-specified time points for Phase 1A. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.

    Time frame: Day -28 (predose), Days 1, 8, and 15 of cycle 1; Days 1 and 15 of cycle 2 and additional cycles; Days 1 and 15 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)

  6. Phase 1A: Number Of Participants Experiencing Severe AEs

    All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and serious adverse event (SAE) recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.

    Time frame: Day -28 through 5 years and 2 months

  7. Phase 1B: Objective Response Rate (ORR)

    The ORR was defined as the percentage of participants in the study whose best overall response was either complete response (CR) or partial response (PR) as assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

    Time frame: Day -28 through 5 years and 2 months

Secondary outcomes

  1. Phase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab

    Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose

  2. Phase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab

    Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose

  3. Phase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab

    Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose

  4. Phase 1A: Half-life (T½) For Tislelizumab

    Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose

  5. Phase 1A - Part 3: Clearance (Cl) For Tislelizumab

    Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose

  6. Phase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs)

    Immunogenicity was summarized by the number and percentage of participants who developed detectable treatment-emergent ADAs, which included positive ADAs and neutralizing antibodies (NAb).

    Time frame: Day 1 of Cycles 1 through 15

  7. Phase 1A: ORR

    The ORR was defined as the percentage of participants in the study whose best overall response was either CR or PR as assessed by investigators based on RECIST v 1.1.

    Time frame: Day -28 through 5 years and 2 months

  8. Phase 1A: CR Rate

    The CR rate was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  9. Phase 1A: PR Rate

    The PR rate was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  10. Phase 1A: Stable Disease (SD) Rate

    The SD rate was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  11. Phase 1A: Progression-free Survival (PFS)

    PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  12. Phase 1A: Overall Survival (OS)

    OS was defined as the time interval between the date of the first study drug dose to the date of death for any cause. Kaplan-Meier methodology was used to estimate OS at various time points. The OS was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  13. Phase 1A: Duration Of Response (DOR)

    DOR for responders (CR or PR) was defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurred earlier. For participants who were alive without progression following the qualifying response, DOR was censored on the date of last evaluable tumor assessment or last follow-up for progression of disease. The DOR was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  14. Phase 1B: Number of Participants Experiencing AEs

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the NCI-CTCAE (v 4.03 2010).

    Time frame: Day -28 through 5 years and 2 months

  15. Phase 1B: Steady State Plasma Trough Concentration Of Tislelizumab

    Time frame: Pre-dose, Day 1 Cycle 5 and every other Cycle in the first 6 months, every 4 cycles in the next 6 months, once every 6 months up to end of treatment (up to 5 years and 2 months)

  16. Phase 1B: PFS

    PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.

    Time frame: Day -28 through 5 years and 2 months

  17. Phase 1B: Disease Control Rate (DCR)

    The DCR was defined as the percentage of participants who achieve CR, PR, and SD based on RECIST v 1.1 in participants with select tumor types.

    Time frame: Day -28 through 5 years and 2 months

  18. Phase 1B: Clinical Benefit Rate (CBR)

    The CBR was defined as the percentage of participants who achieved CR, PR, and durable SD \[SD ≥24 weeks\] based on RECIST v 1.1 in participants with select tumor types.

    Time frame: Day -28 through 5 years and 2 months

  19. Phase 1B: Number Of Participants With Abnormal Physical Examination Values

    A complete physical examination, vital signs (SBP, DBP, pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1B. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.

    Time frame: Day -28 (predose), Days 1, 4, 8, and 15 of cycle 1; Day 1 of cycle 2; through 30 (+/- 7) days after last dose up to 5 years and 2 months

  20. Phase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings

    Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1B. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.

    Time frame: Day -28 (predose), Day 1 of cycle 2 and additional cycles, and 30 (+/- 7) days after last dose up to 5 years and 2 months

  21. Phase 1B: Number Of Participants With Abnormal Electrocardiograms

    Electrocardiograms were obtained at pre-specified time points. Significant QTc prolongation was defined as an interval ≥ 500 msec or an interval which increases by ≥ 60 msec over baseline.

    Time frame: Day -28 (predose), Days 1 and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months

  22. Phase 1B: Number Of Participants With Abnormal Laboratory Values

    Clinical chemistry, hematology, coagulation, and urinalysis will be performed at pre-specified time points for Phase 1A and Phase 1B respectively. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.

    Time frame: Day -28 (predose), Days 1, 8, and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months

  23. Phase 1B: Number Of Participants Experiencing Severe AEs

    All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and SAE recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.

    Time frame: Day -28 through 5 years and 2 months

07

Results

Posted Nov 17, 2021

Participant flow

This study was conducted in 27 centers in 5 countries, enrolled from June 2015 to October 2017 across both Phases, and was initiated in June 2015. After a 5-year period the sponsor decided to close the study as primary and secondary endpoints were met. Participants still on treatment were rolled into a separate long-term extension study (BGB-A317-290-LTE1) to continue treatment.

Participant flow — Overall Study
MilestoneBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1B
Started326267212013335
Completed00000000
Not completed326267212013335
Withdrew: Death222237171610248
Withdrew: Lost to follow-up010000017
Withdrew: Progressive disease00000001
Withdrew: Withdrawal by subject000010030
Withdrew: Study terminated by sponsor133034337
Withdrew: Logistics00000001
Withdrew: Rolled into long-term extension study00000001

Outcome measures

PrimaryPhase 1A: Number of Participants Experiencing Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010).

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1A: Number of Participants Experiencing Adverse Events (AEs)
ParticipantsBGB-A317 Phase 1A
Phase 1A: Number of Participants Experiencing Adverse Events (AEs)114
PrimaryPhase 1A: Number Of Participants With Abnormal Physical Examination Values

A complete physical examination, vital signs (systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1A. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.

Time frame:
Day 1 and Day 15 of each cycle through 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Reported as:
Count of participants · Participants
Phase 1A: Number Of Participants With Abnormal Physical Examination Values
ParticipantsBGB-A317 Phase 1A
At least one postbaseline pulse rate measure ≤ 45 beats per minute (bpm)1
At least one postbaseline pulse rate measure ≥ 120 bpm6
At least one postbaseline SBP measure ≤ 60 millimeters of mercury (mmHg)0
At least one postbaseline SBP measure ≤ 90 mmHg9
At least one postbaseline SBP measure ≥ 160 mmHg17
At least one postbaseline DBP measure ≥ 100 mmHg5
PrimaryPhase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings

Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1A. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.

Time frame:
Day 15 of cycle 1, Day 1 of Cycle 2 and all additional cycles, and 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Reported as:
Count of participants · Participants
Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings
ParticipantsBGB-A317 Phase 1A
Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings0
PrimaryPhase 1A: Number Of Participants With Abnormal Electrocardiograms

Electrocardiograms were obtained at pre-specified time points. Significant QT interval corrected for heart rate (QTc) prolongation was defined as an interval ≥ 500 milliseconds (msec) or an interval which increases by ≥ 60 msec over baseline.

Time frame:
Days 1 and 15 of cycle 1; Day 1 of cycle 2 and all additional cycles; Day 1 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Reported as:
Count of participants · Participants
Phase 1A: Number Of Participants With Abnormal Electrocardiograms
ParticipantsBGB-A317 Phase 1A
At least 1 postbaseline QT corrected using Fridericia's formula (QTcF) Interval measure of >450 msec31
At least 1 postbaseline QTcF Interval measure of > 480 msec9
At least 1 postbaseline QTcF Interval measure of > 500 msec3
At least 1 postbaseline QTcF Interval measure ≤ 30 msec increase from baseline73
At least 1 postbaseline QTcF Interval measure ≤ 30 and ≤ 60 msec increase from baseline35
At least 1 postbaseline QTcF Interval measure > 60 msec increase from baseline8
PrimaryPhase 1A: Number Of Participants With Abnormal Laboratory Values

Clinical chemistry, hematology, coagulation, and urinalysis were performed at pre-specified time points for Phase 1A. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.

Time frame:
Day -28 (predose), Days 1, 8, and 15 of cycle 1; Days 1 and 15 of cycle 2 and additional cycles; Days 1 and 15 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Reported as:
Count of participants · Participants
Phase 1A: Number Of Participants With Abnormal Laboratory Values
ParticipantsBGB-A317 Phase 1A
Alanine Aminotransferase: High6
Albumin: Low11
Alkaline Phosphatase: High7
Aspartate Aminotransferase: High5
Bilirubin: High7
Calcium: Low7
Calcium: High2
Creatinine: High6
Glucose: Low5
Glucose: High13
Hemoglobin: Low6
Leukocytes: Low3
Leukocytes: High0
Lymphocytes: Low22
Lymphocytes: High2
Neutrophils: Low2
Phosphate: Low19
Platelets: Low1
Potassium: Low21
Potassium: High7
Sodium: Low8
Sodium: High0
PrimaryPhase 1A: Number Of Participants Experiencing Severe AEs

All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and serious adverse event (SAE) recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1A: Number Of Participants Experiencing Severe AEs
ParticipantsBGB-A317 Phase 1A
Phase 1A: Number Of Participants Experiencing Severe AEs14
PrimaryPhase 1B: Objective Response Rate (ORR)

The ORR was defined as the percentage of participants in the study whose best overall response was either complete response (CR) or partial response (PR) as assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Number · percentage of participants
Phase 1B: Objective Response Rate (ORR)
percentage of participantsBGB-A317 Phase 1B
Phase 1B: Objective Response Rate (ORR)11.6 (8.41 to 15.57)
SecondaryPhase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab
Time frame:
Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Reported as:
Mean · micrograms/milliliter*day
Phase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab
micrograms/milliliter*dayBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab84.92 ± 35.90332.2 ± 57.33811.8 ± 239.51916.0 ± 458.5512.1 ± 122.21219.0 ± 287.4674.7 ± 173.6
SecondaryPhase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab
Time frame:
Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Reported as:
Mean · micrograms/milliliter
Phase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab
micrograms/milliliterBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab13.5 ± 3.8048.3 ± 6.89147.0 ± 50.8278.0 ± 53.756.8 ± 12.8130.0 ± 29.777.2 ± 13.9
SecondaryPhase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab
Time frame:
Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Reported as:
Mean · hours
Phase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab
hoursBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab3.46 ± 3.122.39 ± 0.892.48 ± 0.732.43 ± 1.831.57 ± 0.654.95 ± 15.41.40 ± 0.82
SecondaryPhase 1A: Half-life (T½) For Tislelizumab
Time frame:
Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Reported as:
Mean · hours
Phase 1A: Half-life (T½) For Tislelizumab
hoursBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A: Half-life (T½) For Tislelizumab10.7 ± 3.9012.9 ± 1.215.0 ± 14.414.5 ± 4.0417.1 ± 8.1419.6 ± 7.6316.8 ± 5.50
SecondaryPhase 1A - Part 3: Clearance (Cl) For Tislelizumab
Time frame:
Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Reported as:
Geometric mean · liters/day
Phase 1A - Part 3: Clearance (Cl) For Tislelizumab
liters/dayBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A - Part 3: Clearance (Cl) For Tislelizumab0.186 (0.135 to 0.256)
SecondaryPhase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs)

Immunogenicity was summarized by the number and percentage of participants who developed detectable treatment-emergent ADAs, which included positive ADAs and neutralizing antibodies (NAb).

Time frame:
Day 1 of Cycles 1 through 15
Reported as:
Number · Participants
Phase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs)
ParticipantsBGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kg and BGB-A317 Phase 1BBGB-A317 Phase 1A - Part 3 - 200.0 mg/kg
Phase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs)16516433
SecondaryPhase 1A: ORR

The ORR was defined as the percentage of participants in the study whose best overall response was either CR or PR as assessed by investigators based on RECIST v 1.1.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Number · percentage of participants
Phase 1A: ORR
percentage of participantsBGB-A317 Phase 1A
Phase 1A: ORR18.1 (11.57 to 26.33)
SecondaryPhase 1A: CR Rate

The CR rate was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1A: CR Rate
ParticipantsBGB-A317 Phase 1A
Phase 1A: CR Rate6
SecondaryPhase 1A: PR Rate

The PR rate was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1A: PR Rate
ParticipantsBGB-A317 Phase 1A
Phase 1A: PR Rate15
SecondaryPhase 1A: Stable Disease (SD) Rate

The SD rate was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1A: Stable Disease (SD) Rate
ParticipantsBGB-A317 Phase 1A
Phase 1A: Stable Disease (SD) Rate42
SecondaryPhase 1A: Progression-free Survival (PFS)

PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Median · months
Phase 1A: Progression-free Survival (PFS)
monthsBGB-A317 Phase 1A
Phase 1A: Progression-free Survival (PFS)3.5 (2.1 to 3.8)
SecondaryPhase 1A: Overall Survival (OS)

OS was defined as the time interval between the date of the first study drug dose to the date of death for any cause. Kaplan-Meier methodology was used to estimate OS at various time points. The OS was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Median · months
Phase 1A: Overall Survival (OS)
monthsBGB-A317 Phase 1A
Phase 1A: Overall Survival (OS)13.6 (9.9 to 17.5)
SecondaryPhase 1A: Duration Of Response (DOR)

DOR for responders (CR or PR) was defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurred earlier. For participants who were alive without progression following the qualifying response, DOR was censored on the date of last evaluable tumor assessment or last follow-up for progression of disease. The DOR was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Median · months
Phase 1A: Duration Of Response (DOR)
monthsBGB-A317 Phase 1A
Phase 1A: Duration Of Response (DOR)14.6 (8.3 to NA)
SecondaryPhase 1B: Number of Participants Experiencing AEs

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the NCI-CTCAE (v 4.03 2010).

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number of Participants Experiencing AEs
ParticipantsBGB-A317 Phase 1B
Phase 1B: Number of Participants Experiencing AEs322
SecondaryPhase 1B: Steady State Plasma Trough Concentration Of Tislelizumab
Time frame:
Pre-dose, Day 1 Cycle 5 and every other Cycle in the first 6 months, every 4 cycles in the next 6 months, once every 6 months up to end of treatment (up to 5 years and 2 months)
Reported as:
Geometric mean · micrograms/milliliter
Phase 1B: Steady State Plasma Trough Concentration Of Tislelizumab
micrograms/milliliterBGB-A317 Phase 1B
Non-Small Cell Lung Cancer63.9 ± 47.8
Ovarian Cancer90.4 ± 66.7
Gastric Cancer40.7 ± 91.4
Hepatocellular Carcinoma54.4 ± 56.8
Head & Neck Squamous Cell Carcinoma77.4 ± 45.8
Esophageal Carcinoma57.8 ± 62.4
Triple Negative Breast Cancer47.8 ± 78.9
Cholangio Carcinoma65.7 ± 47.9
Other Solid Tumors80.4 ± 43.5
SecondaryPhase 1B: PFS

PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Median · months
Phase 1B: PFS
monthsBGB-A317 Phase 1B
Phase 1B: PFS2.1 (2.0 to 2.2)
SecondaryPhase 1B: Disease Control Rate (DCR)

The DCR was defined as the percentage of participants who achieve CR, PR, and SD based on RECIST v 1.1 in participants with select tumor types.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Number · percentage of participants
Phase 1B: Disease Control Rate (DCR)
percentage of participantsBGB-A317 Phase 1B
Phase 1B: Disease Control Rate (DCR)41.2 (35.87 to 46.67)
SecondaryPhase 1B: Clinical Benefit Rate (CBR)

The CBR was defined as the percentage of participants who achieved CR, PR, and durable SD \[SD ≥24 weeks\] based on RECIST v 1.1 in participants with select tumor types.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Number · percentage of participants
Phase 1B: Clinical Benefit Rate (CBR)
percentage of participantsBGB-A317 Phase 1B
Phase 1B: Clinical Benefit Rate (CBR)24.5 (19.97 to 29.45)
SecondaryPhase 1B: Number Of Participants With Abnormal Physical Examination Values

A complete physical examination, vital signs (SBP, DBP, pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1B. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.

Time frame:
Day -28 (predose), Days 1, 4, 8, and 15 of cycle 1; Day 1 of cycle 2; through 30 (+/- 7) days after last dose up to 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number Of Participants With Abnormal Physical Examination Values
ParticipantsBGB-A317 Phase 1B
At least one postbaseline pulse rate measure ≤ 45 bpm5
At least one postbaseline pulse rate measure ≥ 120 bpm26
At least one postbaseline SBP measure ≤ 60 mmHg1
At least one postbaseline SBP measure ≤ 90 mmHg24
At least one postbaseline SBP measure ≥ 160 mmHg30
At least one postbaseline DBP measure ≥ 100 mmHg12
SecondaryPhase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings

Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1B. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.

Time frame:
Day -28 (predose), Day 1 of cycle 2 and additional cycles, and 30 (+/- 7) days after last dose up to 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings
ParticipantsBGB-A317 Phase 1B
Phase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings0
SecondaryPhase 1B: Number Of Participants With Abnormal Electrocardiograms

Electrocardiograms were obtained at pre-specified time points. Significant QTc prolongation was defined as an interval ≥ 500 msec or an interval which increases by ≥ 60 msec over baseline.

Time frame:
Day -28 (predose), Days 1 and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number Of Participants With Abnormal Electrocardiograms
ParticipantsBGB-A317 Phase 1B
At least 1 postbaseline QTcF Interval measure > 450 msec84
At least 1 postbaseline QTcF Interval measure > 480 msec24
At least 1 postbaseline QTcF Interval measure > 500 msec10
At least 1 postbaseline QTcF Interval measure ≤ 30 msec increase from baseline241
At least 1 postbaseline QTcF Interval measure >30 and ≤ 60 msec increase from baseline67
At least 1 postbaseline QTcF Interval measure > 60 msec increase22
SecondaryPhase 1B: Number Of Participants With Abnormal Laboratory Values

Clinical chemistry, hematology, coagulation, and urinalysis will be performed at pre-specified time points for Phase 1A and Phase 1B respectively. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.

Time frame:
Day -28 (predose), Days 1, 8, and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number Of Participants With Abnormal Laboratory Values
ParticipantsBGB-A317 Phase 1B
Alanine Aminotransferase: High21
Albumin: Low42
Alkaline Phosphatase: High21
Aspartate Aminotransferase: High21
Bilirubin: High22
Calcium: Low12
Calcium: High7
Creatinine: High20
Glucose: Low8
Glucose: High32
Hemoglobin: Low19
Leukocytes: Low8
Leukocytes: High1
Lymphocytes: Low33
Lymphocytes: High2
Neutrophils: Low5
Phosphate: Low42
Platelets: Low3
Potassium: Low35
Potassium: High4
Sodium: Low25
Sodium: High1
SecondaryPhase 1B: Number Of Participants Experiencing Severe AEs

All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and SAE recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.

Time frame:
Day -28 through 5 years and 2 months
Reported as:
Count of participants · Participants
Phase 1B: Number Of Participants Experiencing Severe AEs
ParticipantsBGB-A317 Phase 1B
Phase 1B: Number Of Participants Experiencing Severe AEs27

Adverse events

Collected over Day -28 through 5 years and 2 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BGB-A317 Phase 1A97/116 (83.6%)40/116 (34.5%)112/116 (96.6%)
BGB-A317 Phase 1B249/335 (74.3%)131/335 (39.1%)302/335 (90.1%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventBGB-A317 Phase 1ABGB-A317 Phase 1B
PneumoniaInfections and infestations4/11616/335
Abdominal painGastrointestinal disorders3/1163/335
ColitisGastrointestinal disorders3/1162/335
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1161/335
PneumonitisRespiratory, thoracic and mediastinal disorders1/1168/335
VomitingGastrointestinal disorders2/1166/335
PyrexiaGeneral disorders2/1166/335
AscitesGastrointestinal disorders2/1164/335
NauseaGastrointestinal disorders2/1163/335
Back painMusculoskeletal and connective tissue disorders2/1164/335
Most frequent other events
Showing 10 of 66
Most frequent other events
EventBGB-A317 Phase 1ABGB-A317 Phase 1B
FatigueGeneral disorders47/11680/335
NauseaGastrointestinal disorders41/11671/335
DiarrhoeaGastrointestinal disorders33/11649/335
ConstipationGastrointestinal disorders28/11651/335
Back painMusculoskeletal and connective tissue disorders26/11640/335
Decreased appetiteMetabolism and nutrition disorders20/11674/335
Abdominal painGastrointestinal disorders25/11642/335
RashSkin and subcutaneous tissue disorders23/11639/335
PruritusSkin and subcutaneous tissue disorders21/11638/335
VomitingGastrointestinal disorders19/11642/335

Baseline characteristics

Age, Continuous
Age, Continuous(years)BGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1BTotal
Mean54.7 ± 7.0259.1 ± 11.1557.8 ± 13.3257.1 ± 8.1363.6 ± 10.0962.6 ± 11.1458.4 ± 17.7659.5 ± 11.9259.6 ± 11.96
Age, Customized
Age, Customized(Participants)BGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1BTotal
< 65 Years3181668116217285
≥ 65 Years081011397118166
Sex: Female, Male
Sex: Female, Male(Participants)BGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1BTotal
Female31215410125144205
Male0141131188191246
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1BTotal
Hispanic or Latino0200000810
Not Hispanic or Latino324267212013322436
Unknown or Not Reported000000055
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BGB-A317 Phase 1A - Part 1 - 0.5 mg/kgBGB-A317 Phase 1A - Part 1 - 2.0 mg/kgBGB-A317 Phase 1A - Part 1 - 5.0 mg/kgBGB-A317 Phase 1A - Part 1 - 10.0 mg/kgBGB-A317 Phase 1A - Part 2 - 2.0 mg/kgBGB-A317 Phase 1A - Part 2 - 5.0 mg/kgBGB-A317 Phase 1A - Part 3 - 200.0 mg/kgBGB-A317 Phase 1BTotal
American Indian or Alaska Native000000011
Asian0230131120130
Chinese (enrolled from Taiwan sites)00000006161
Non-Chinese02301315969
Black or African American000000055
Native Hawaiian or Other Pacific Islander000000022
White322237191611189290
Other02001111823
08

Study locations

27 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77024-2545, United States
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • Prince of Wales Hospital
    Sydney, New South Wales, Australia
  • Tasman Oncology Research Ltd
    Southport, Queensland 4216, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia, Australia
  • Monash Health
    Clayton, Victoria, Australia
  • Peter MacCallum Cancer Centre
    East Melbourne, Victoria, Australia
  • Austin Health Hospital
    Heidelberg, Victoria, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria, Australia
  • Linear Clinical Research/Sir Charles Gairdner Hospital
    Nedlands, Western Australia, Australia
  • Seoul National University Bundang Hospital
    Seongnam, Kyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 3080, Korea, Republic of
  • Asan Medical Center
    Seoul, 5505, Korea, Republic of
  • Auckland City Hospital
    Grafton, 1023, New Zealand
  • Waikato
    Hamilton, 3204, New Zealand
  • Wellington Hospital
    Wellington, 6022, New Zealand
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 83301, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 33305, Taiwan
  • Chang Gung Memorial Hospital, Sachin
    Taoyuan, 61363, Taiwan
09

References and documents

Publications

  • Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020 Jun;8(1):e000453. doi: 10.1136/jitc-2019-000453. PubMed 32540858 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Aug 2020, 62 months.

Results were first posted in Nov 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2015
First posted
Apr 3, 2015
StartActual
Jun 2, 2015
Primary completionActual
Aug 12, 2020
CompletionActual
Aug 12, 2020
Results first posted
Nov 17, 2021
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02407990
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Apr 3, 2015
Start date
Jun 2, 2015
Primary completion
Aug 12, 2020
Completion
Aug 12, 2020
Results posted
Nov 17, 2021
Last update
Nov 17, 2021

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion